Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Anesth Analg. 2021 Apr 1;132(4):1156–1163. doi: 10.1213/ANE.0000000000005302

Figure 5. Blocking IL-1 signaling does not alleviate HNCP.

Figure 5.

A) Intrathecal injection of IL-1 receptor antagonist (IL-1ra) does not reduce mEERL tumor-induced pain hypersensitivity. IL-1ra was injected daily from day 15 to day 21, 2-way ANOVA (drug effect) F(1, 8) = 2.61, p = 0.15 (no significant difference between genotype), n = 5 mice/group. B) IL-1ra reduces the expression of Il1b in the spinal cord 21 days after cancer cells injection (unpaired t-test p = 0.0003, t = 6.02, df = 8). C) Serum IL-1β assessed by ELISA at 21 days (unpaired t-test p = 0.210, t = 1.36, df = 8), n = 5 mice/group.